IL6 and Duchenne muscular dystrophy: The controversial results observed in mdx mice after using an antibody directed against IL-6 (tocilizumab, RoActemra®, Roche, Basel, Switzerland) requires careful consideration before it can be part of the list of putative molecules for DMD treatment (Table 4).